(Q35145698)

6 August 2017

1 reference

title

Radical radiotherapy for prostate cancer (English)

1 reference

6 August 2017

1 reference

Parker CC

1

1 reference

6 August 2017

Dearnaley DP

series ordinal

2

1 reference

6 August 2017

publication date

1 June 2003

1 reference

6 August 2017

published in

Cancer Treatment Reviews

1 reference

6 August 2017

volume

29

1 reference

6 August 2017

issue

3

1 reference

6 August 2017

page(s)

161-169

1 reference

Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900070-7

7 January 2021

High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900070-7

7 January 2021

Reduction of small and large bowel irradiation using an optimized intensity-modulated pelvic radiotherapy technique in patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900070-7

7 January 2021

Potential improvements in the therapeutic ratio of prostate cancer irradiation: dose escalation of pathologically identified tumour nodules using intensity modulated radiotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900070-7

7 January 2021

Comparison of MRI with CT for the radiotherapy planning of prostate cancer: a feasibility study

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900070-7

7 January 2021

Initial clinical assessment of CT-MRI image fusion software in localization of the prostate for 3D conformal radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900070-7

7 January 2021

Evaluating the effect of rectal distension and rectal movement on prostate gland position using cine MRI

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900070-7

7 January 2021

Implementation and utility of a daily ultrasound-based localization system with intensity-modulated radiotherapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900070-7

7 January 2021

Positioning errors and prostate motion during conformal prostate radiotherapy using on-line isocentre set-up verification and implanted prostate markers

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900070-7

7 January 2021

Daily prostate targeting using implanted radiopaque markers

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900070-7

7 January 2021

Intrafraction prostate motion during IMRT for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900070-7

7 January 2021

Defining a dose-response relationship with radiotherapy for prostate cancer: is more really better?

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900070-7

7 January 2021

Declining rates of extracapsular extension after radical prostatectomy: evidence for continued stage migration

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900070-7

7 January 2021

Gleason scores of prostate biopsy and radical prostatectomy specimens over the past 10 years: is there evidence for systematic upgrading?

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900070-7

7 January 2021

Changing prostate-specific antigen outcome after surgery or radiotherapy for localized prostate cancer during the prostate-specific antigen era

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900070-7

7 January 2021

Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900070-7

7 January 2021

Survival advantage from higher-dose radiation therapy for clinically localized prostate cancer treated on the Radiation Therapy Oncology Group trials

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900070-7

7 January 2021

Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900070-7

7 January 2021

Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900070-7

7 January 2021

Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900070-7

7 January 2021

Re: All-cause mortality in randomized trials of cancer screening

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900070-7

7 January 2021

Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: The Telecom Study

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900070-7

7 January 2021

The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900070-7

7 January 2021

Understanding and appreciating overdiagnosis in the PSA era

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900070-7

7 January 2021

Survival prospects after screen-detection of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900070-7

7 January 2021

Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900070-7

7 January 2021

Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900070-7

7 January 2021

Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900070-7

7 January 2021

An interinstitutional and interspecialty comparison of treatment outcome data for patients with prostate carcinoma based on predefined prognostic categories and minimum follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900070-7

7 January 2021

Complications from treatment for prostate carcinoma among men in the Detroit area

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900070-7

7 January 2021

Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900070-7

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900070-7

7 January 2021

Salvage radiotherapy for PSA failure after radical prostatectomy.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900070-7

7 January 2021

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900070-7

7 January 2021

Changes in early and late radiation responses with altered dose fractionation: implications for dose-survival relationships

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900070-7

7 January 2021

Fractionation and protraction for radiotherapy of prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900070-7

7 January 2021

Is alpha/beta for prostate tumors really low?

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900070-7

7 January 2021

A simple analytic derivation suggests that prostate cancer alpha/beta ratio is low

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900070-7

7 January 2021

Individualization of dose prescription based on normal-tissue dose-volume and radiosensitivity data.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900070-7

7 January 2021

Relationships between DVHs and late rectal bleeding after radiotherapy for prostate cancer: analysis of a large group of patients pooled from three institutions

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900070-7

7 January 2021

10.1016/S0305-7372(03)00070-7

Identifiers

DOI

1 reference

6 August 2017

1 reference